New Delhi, Feb. 25 -- Ahmedabad-based drugmaker Zydus Lifesciences plans to launch its semaglutide injection brands upon patent expiry of the drug in India. The drugmaker said it will launch the drug in a novel single-pen device that is reusable. Zydus has exclusive rights to the device.

The patent for semaglutide is set to expire on 20 March 2026, with several Indian drugmakers including Dr. Reddy's and Sun Pharma gearing up for Day-one launches.

Zydus has received regulatory approval from the Drug Controller General of India (DCGI) to market and manufacture semaglutide to treat type-2 diabetes and obesity.

The drug will be launched under brand names Semaglyn, Mashema, and Alterme, the company said in a release on Wednesday.

While th...